Ribociclib in premenopausal women with advanced breast cancer
Mené sur 672 patientes atteintes d'un cancer du sein HR+ de stade avancé avant la ménopause, cet essai de phase III évalue l'efficacité, du point de vue de la survie sans progression, et la toxicité de l'ajout du ribociclib à une hormonothérapie
Inhibition of cell-cycle progression using inhibitors of cyclin-dependent kinases (CDKs) 4 and 6 is an effective treatment strategy in hormone-receptor-positive breast cancer. Three inhibitors of CDKs 4 and 6—palbociclib, ribociclib, and abemaciclib—are approved by the US Food and Drug Administration for treatment of advanced breast cancer. The approval for palbociclib and abemaciclib, based on subgroup analyses from the PALOMA-31 and MONARCH-22 trials, includes premenopausal and perimenopausal patients provided that endocrine therapy is combined with ovarian suppression using a gonadotropin-releasing hormone (GnRH) analogue.
The Lancet Oncology , commentaire, 2017